Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' …
B Glintborg, M Østergaard, NS Krogh… - Annals of the …, 2010 - ard.bmj.com
Objectives To use prospectively registered data from the Danish nationwide rheumatological
database (DANBIO) to describe disease activity, clinical response, treatment duration and …
database (DANBIO) to describe disease activity, clinical response, treatment duration and …
Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti–tumor necrosis factor α therapy: results from the …
B Glintborg, M Østergaard, L Dreyer… - Arthritis & …, 2011 - Wiley Online Library
Objective To investigate disease activity, treatment response, and drug survival, and
predictors thereof, among Danish patients with psoriatic arthritis (PsA) receiving their first …
predictors thereof, among Danish patients with psoriatic arthritis (PsA) receiving their first …
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO …
B Glintborg, IJ Sørensen, AG Loft… - Annals of the …, 2017 - ard.bmj.com
Objectives According to guidelines, a nationwide non-medical switch from originator (INX,
Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients …
Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients …
Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from …
B Glintborg, M Østergaard, NS Krogh… - Arthritis & …, 2013 - Wiley Online Library
Objective To describe the frequency of treatment switching and outcomes among patients
with psoriatic arthritis (PsA) who switched tumor necrosis factor α inhibitor (TNFi) agents in …
with psoriatic arthritis (PsA) who switched tumor necrosis factor α inhibitor (TNFi) agents in …
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 …
B Glintborg, AG Loft, E Omerovic… - Annals of the …, 2019 - ard.bmj.com
Objectives Real-world evidence on effectiveness of switching to biosimila r etanercept is
scarce. In Denmark, a nationwide guideline of mandatory switch from 50 mg originator (ETA) …
scarce. In Denmark, a nationwide guideline of mandatory switch from 50 mg originator (ETA) …
Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the …
B Glintborg, M Østergaard, NS Krogh, U Tarp… - Annals of the …, 2013 - ard.bmj.com
Objective To investigate frequencies and reasons for switching, treatment responses and
drug survival in patients with ankylosing spondylitis (AS) switching tumour-necrosis-factor-α …
drug survival in patients with ankylosing spondylitis (AS) switching tumour-necrosis-factor-α …
Waiting for JAK inhibitor safety data
TW Kragstrup, B Glintborg, AL Svensson… - RMD open, 2022 - rmdopen.bmj.com
The US Food and Drug Administration (FDA) has recently added a new 'black box
warning'on all currently approved Janus kinase (JAK) inhibitors indicated for the treatment of …
warning'on all currently approved Janus kinase (JAK) inhibitors indicated for the treatment of …
Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry
HC Leffers, M Østergaard, B Glintborg… - Annals of the …, 2011 - ard.bmj.com
Objectives To describe drug survival, disease activity and clinical response in patients with
rheumatoid arthritis (RA) treated with abatacept or tocilizumab in routine care, based on …
rheumatoid arthritis (RA) treated with abatacept or tocilizumab in routine care, based on …
The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries
P Højgaard, B Glintborg, LE Kristensen… - …, 2016 - academic.oup.com
Objectives. To investigate the impact of obesity on response to the first TNF-α inhibitor (TNFI)
treatment course in patients with PsA followed in routine care. Methods. We performed an …
treatment course in patients with PsA followed in routine care. Methods. We performed an …
Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers
K Hellgren, L Dreyer, EV Arkema, B Glintborg… - Annals of the …, 2017 - ard.bmj.com
Background Safety data on cancer risks following tumour necrosis factor α inhibitors (TNFi)
in patients with spondyloarthritis (SpA)(here defined as ankylosing spondylitis (AS) …
in patients with spondyloarthritis (SpA)(here defined as ankylosing spondylitis (AS) …